fingolimod hydrochloride has been researched along with Hepatopulmonary Syndrome in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baweja, S; Bihari, C; Kumar, G; Kumar, J; Kumari, A; Maiwall, R; Mourya, AK; Negi, P; Rastogi, A; Reddy, GS; Sarin, SK; Sarohi, V; Sood, AK; Subudhi, PD; Thangariyal, S; Tomar, A; Tripathi, DM; Vashistha, C | 1 |
1 other study(ies) available for fingolimod hydrochloride and Hepatopulmonary Syndrome
| Article | Year |
|---|---|
Hepatopulmonary syndrome is associated with low sphingosine-1-phosphate levels and can be ameliorated by the functional agonist fingolimod.
Topics: Animals; Fingolimod Hydrochloride; Hepatopulmonary Syndrome; Inflammation; Liver Cirrhosis; Mice; Niacinamide; Rats; Rats, Sprague-Dawley | 2023 |